JP2004502460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502460A5 JP2004502460A5 JP2002509500A JP2002509500A JP2004502460A5 JP 2004502460 A5 JP2004502460 A5 JP 2004502460A5 JP 2002509500 A JP2002509500 A JP 2002509500A JP 2002509500 A JP2002509500 A JP 2002509500A JP 2004502460 A5 JP2004502460 A5 JP 2004502460A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- nucleic acid
- protective
- immune response
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710194807 Protective antigen Proteins 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 230000001681 protective effect Effects 0.000 description 17
- 241000193738 Bacillus anthracis Species 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 15
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 7
- 229940065181 bacillus anthracis Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 208000022338 anthrax infection Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0016702.3A GB0016702D0 (en) | 2000-07-08 | 2000-07-08 | Expression system |
| PCT/GB2001/003065 WO2002004646A1 (en) | 2000-07-08 | 2001-07-06 | Expression system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011180293A Division JP2012010706A (ja) | 2000-07-08 | 2011-08-22 | 発現系 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502460A JP2004502460A (ja) | 2004-01-29 |
| JP2004502460A5 true JP2004502460A5 (enExample) | 2008-08-21 |
Family
ID=9895205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002509500A Pending JP2004502460A (ja) | 2000-07-08 | 2001-07-06 | 発現系 |
| JP2011180293A Pending JP2012010706A (ja) | 2000-07-08 | 2011-08-22 | 発現系 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011180293A Pending JP2012010706A (ja) | 2000-07-08 | 2011-08-22 | 発現系 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7537771B2 (enExample) |
| EP (2) | EP1301606A1 (enExample) |
| JP (2) | JP2004502460A (enExample) |
| CN (2) | CN1322134C (enExample) |
| AU (1) | AU2007201553B8 (enExample) |
| CA (2) | CA2658217A1 (enExample) |
| GB (1) | GB0016702D0 (enExample) |
| RU (2) | RU2385348C2 (enExample) |
| WO (1) | WO2002004646A1 (enExample) |
| ZA (1) | ZA200210206B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0016702D0 (en) | 2000-07-08 | 2000-08-23 | Secr Defence Brit | Expression system |
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| AU2003278776A1 (en) * | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| AU2003303307B2 (en) | 2002-11-15 | 2006-12-07 | Gen-Probe Incorporated | Assay and compositions for detection of bacillus anthracis nucleic acid |
| EP1670505B1 (en) | 2003-09-18 | 2012-11-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dna promoters and anthrax vaccines |
| FR2860005A1 (fr) * | 2003-09-23 | 2005-03-25 | Univ Aix Marseille Ii | Methode de detection d'agents bacteriens ou viraux de bioterrorisme |
| WO2005030991A1 (fr) * | 2003-09-23 | 2005-04-07 | Universite De La Mediterranee (Aix-Marseille Ii) | Methode de detection d’agents bacteriens ou viraux de bioterrorisme |
| GB0401036D0 (en) * | 2004-01-17 | 2004-02-18 | Royal Holloway University Of L | Improvements in or relating to vaccination |
| US8101735B2 (en) | 2004-06-16 | 2012-01-24 | Health Protection Agency | Preparation of protective antigen |
| US7355027B2 (en) | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
| US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
| CN100336908C (zh) * | 2004-09-10 | 2007-09-12 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种制备重组炭疽保护性抗原的方法及其专用表达质粒 |
| WO2006068647A1 (en) * | 2004-12-20 | 2006-06-29 | United States Army Medical Research And Materiel Command | Internal positive control for probe-based nucleic acid molecule assays and methods of making and using thereof |
| GB0504940D0 (en) * | 2005-03-10 | 2005-04-20 | Secr Defence | Vaccine formulation |
| US7947268B2 (en) | 2005-11-14 | 2011-05-24 | University Of Maryland, Baltimore | Salmonella based oral vaccines for anthrax |
| GB0525213D0 (en) * | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
| CA2634163A1 (en) * | 2005-12-22 | 2007-06-28 | Iq Corporation | Compositions and methods of modulating the immune response |
| GB0607462D0 (en) | 2006-04-13 | 2006-05-24 | Avecia Ltd | Assay |
| JP2008231063A (ja) * | 2007-03-22 | 2008-10-02 | Takano Foods Kk | 納豆菌ワクチン |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| MX2009011523A (es) | 2007-04-27 | 2009-11-09 | Dow Global Technologies Inc | Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas. |
| CA2738621C (en) | 2008-10-02 | 2017-01-31 | Pharmathene Inc. | Anthrax vaccine formulation and uses thereof |
| US20110256172A1 (en) * | 2008-10-14 | 2011-10-20 | The Regents Of The University Of Michigan | Epitope-targeted anthrax vaccine |
| US20100183675A1 (en) * | 2009-01-22 | 2010-07-22 | Allan Watkinson | Stable vaccine compositions and methods of use |
| US8187611B2 (en) * | 2009-10-29 | 2012-05-29 | Albert Einstein College Of Medicine Of Yeshiva University | Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof |
| US20110110968A1 (en) * | 2009-11-12 | 2011-05-12 | Stanley Goldman | Human optimized Bacillus anthracis protective antigen |
| CN101798565B (zh) * | 2010-02-26 | 2013-08-07 | 中国人民解放军军事医学科学院生物工程研究所 | 能在芽孢表面展示pa20蛋白的炭疽芽孢杆菌及其应用 |
| RU2633504C1 (ru) * | 2016-12-27 | 2017-10-12 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) | Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц |
| RU2633508C1 (ru) * | 2016-12-27 | 2017-10-12 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) | Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц |
| WO2020116686A1 (ko) * | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2115433C1 (ru) * | 1992-08-28 | 1998-07-20 | Научно-исследовательский институт микробиологии МО РФ | Вакцина сибиреязвенная комбинированная |
| US5677274A (en) | 1993-02-12 | 1997-10-14 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Anthrax toxin fusion proteins and related methods |
| RU2110575C1 (ru) * | 1995-07-19 | 1998-05-10 | Государственное Федеральное предприятие Государственный научный центр прикладной микробиологии | Рекомбинантная плазмидная днк pro pf 5, определяющая синтез капсульного антигена fi возбудителя чумы и протективного антигена возбудителя сибирской язвы, и способ конструирования рекомбинантной плазмидной днк pro pf5 |
| WO2000002522A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Anthrax vaccine |
| GB0016702D0 (en) | 2000-07-08 | 2000-08-23 | Secr Defence Brit | Expression system |
-
2000
- 2000-07-08 GB GBGB0016702.3A patent/GB0016702D0/en not_active Ceased
-
2001
- 2001-07-06 CN CNB018124097A patent/CN1322134C/zh not_active Expired - Fee Related
- 2001-07-06 EP EP01947659A patent/EP1301606A1/en not_active Withdrawn
- 2001-07-06 CN CNA2006101290967A patent/CN101012458A/zh active Pending
- 2001-07-06 CA CA002658217A patent/CA2658217A1/en not_active Abandoned
- 2001-07-06 RU RU2004134341/13A patent/RU2385348C2/ru not_active IP Right Cessation
- 2001-07-06 US US10/332,282 patent/US7537771B2/en not_active Expired - Fee Related
- 2001-07-06 EP EP07005671.8A patent/EP1808489B1/en not_active Expired - Lifetime
- 2001-07-06 WO PCT/GB2001/003065 patent/WO2002004646A1/en not_active Ceased
- 2001-07-06 JP JP2002509500A patent/JP2004502460A/ja active Pending
- 2001-07-06 RU RU2003103779/13A patent/RU2270865C2/ru not_active IP Right Cessation
- 2001-07-06 CA CA2413045A patent/CA2413045C/en not_active Expired - Lifetime
-
2002
- 2002-12-17 ZA ZA200210206A patent/ZA200210206B/xx unknown
-
2007
- 2007-03-26 US US11/728,384 patent/US8313928B2/en not_active Expired - Fee Related
- 2007-04-05 AU AU2007201553A patent/AU2007201553B8/en not_active Ceased
-
2011
- 2011-08-22 JP JP2011180293A patent/JP2012010706A/ja active Pending
-
2012
- 2012-09-26 US US13/627,071 patent/US9346860B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502460A5 (enExample) | ||
| RU2003103779A (ru) | Экспрессионная система | |
| JP2002510494A5 (enExample) | ||
| ATE292685T1 (de) | Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe | |
| JP2001081042A5 (enExample) | ||
| RU2004134341A (ru) | Экспрессирующая система | |
| CA2230033A1 (en) | Production of infectious respiratory syncytial virus from cloned nucleotide sequences | |
| JP2002537791A5 (enExample) | ||
| JP2017536835A5 (enExample) | ||
| JP2002542827A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| DK2311848T3 (da) | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion | |
| JP6958818B2 (ja) | ヒトパピローマウイルスタイプ５８のｌ１タンパク質の突然変異 | |
| JP2003510050A5 (enExample) | ||
| WO2001045639A3 (en) | Methods for protecting against lethal infection with bacillus anthracis | |
| WO2006039045A3 (en) | Adenoviral vectors able to transduce apcs, potential use in immune response generation | |
| CA2572555A1 (en) | Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine | |
| CA2135201A1 (en) | Universal coronavirus vaccine | |
| López et al. | In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus | |
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| Hsu et al. | Characterization of polymorphism displayed by the coat protein mutants of tomato bushy stunt virus | |
| JP2020509770A5 (enExample) | ||
| BR112020024694A2 (pt) | Mutante de proteína l1 do tipo 39 de papilomavírus humano | |
| AU704594B2 (en) | Production of recombinant peptides as natural hydrophobic peptide analogues | |
| JP2005512518A5 (enExample) |